Document Detail


New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.
MedLine Citation:
PMID:  22956883     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Actinic keratosis is a common disease in older, fair-skinned people, and is a consequence of cumulative ultraviolet exposure. It is part of a disease continuum in photodamaged skin that may lead to invasive squamous cell carcinoma. Treatment options frequently used include cryosurgery and topical pharmacologic agents, which are examples of lesion-directed and field-directed strategies. Ingenol mebutate gel was recently approved by the US Food and Drug Administration for topical treatment of actinic keratosis. While the mechanism of action of ingenol mebutate is not fully understood, in vitro and in vivo studies using tumor models indicate it has multiple mechanisms. Ingenol mebutate directly induces cell death by mitochondrial swelling and loss of cell membrane integrity preferentially in transformed keratinocytes. It promotes an inflammatory response characterized by infiltration of neutrophils and other immunocompetent cells that kills remaining tumor cells. The ability of ingenol mebutate to eliminate mutant p53 patches in ultraviolet-irradiated mouse skin suggests that it may have the potential to treat chronically ultraviolet-damaged skin. In human studies, ingenol mebutate achieved high clearance of actinic keratosis on the head and body after 2-3 consecutive daily treatments when measured by complete or partial clearance of lesions. Localized inflammatory skin responses were generally mild to moderate and resolved in less than a month.
Authors:
Brian Berman
Related Documents :
2664473 - Resistance to oncogenic transformation in revertant r1 of human ras-transformed nih 3t3...
7142283 - A study of the influence of mevalonic acid and its metabolites on the morphology of swi...
23462723 - Ing1b-inducible microrna203 inhibits cell proliferation.
Publication Detail:
Type:  Journal Article     Date:  2012-08-24
Journal Detail:
Title:  Clinical, cosmetic and investigational dermatology     Volume:  5     ISSN:  1178-7015     ISO Abbreviation:  Clin Cosmet Investig Dermatol     Publication Date:  2012  
Date Detail:
Created Date:  2012-09-07     Completed Date:  2012-10-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101543449     Medline TA:  Clin Cosmet Investig Dermatol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  111-22     Citation Subset:  -    
Affiliation:
University of Miami Miller School of Medicine, Miami, and Center for Clinical and Cosmetic Research, Aventura, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sebusuppressive efficacy of the antioxidant bis-ethylhexyl hydroxydimethoxy benzylmalonate in the tr...
Next Document:  Lenalidomide for the treatment of relapsed and refractory multiple myeloma.